The French Rare Disease Reference Center for congenital diaphragmatic hernia (CDH) was created in 2008, to implement a national protocol for foetuses and children with this serious condition. Neonatal mortality from CDH is 30-40%, mainly due to pulmonary hypoplasia and persistent pulmonary hypertension, and half of those who live have high respiratory, nutritional and digestive morbidity. CDH management requires long-term and specialised multidisciplinary care. It has been well established that a standardised management protocol improves the prognosis of children with CDH.
INTRODUCTION
Congenital diaphragmatic hernia (CDH) is usually associated with herniation of the abdominal viscera into the thoracic cavity and the pulmonary development abnormalities that are responsible for pulmonary hypoplasia and structural and functional abnormalities of pulmonary circulation. The incidence of this malformation is close to one in 3500 births. The functional consequences of CDH are particularly heterogeneous, with some asymptomatic children at birth, while others encounter major difficulties in adapting to extrauterine life, sometimes leading to death. Congenital diaphragmatic hernia is usually sporadic, although rare familial forms have been reported. Congenital diaphragmatic hernias are associated with other malformations and, or, chromosomal abnormalities in 40% of cases, including Trisomy 18 or 13, Fryns syndrome, Denys-Drash syndrome and Pallister-Killian syndrome (1) . The hernia can be left-or right-sided or bilateral, but in 80% of cases, the diaphragmatic defect is located at the posterolateral part of the left dome.
The pathophysiology of this malformation is complex, and, despite progress in resuscitation techniques, neonatal mortality remains close to 30-40%, mainly due to pulmonary hypoplasia and persistent pulmonary hypertension (PPHN) (2) . About 10% of children die following the neonatal period, from respiratory and, or, digestive complications occurring in their first years of life (3) . In addition, CDH is associated with high morbidity, which affects about half of the children who live. The main sequelae observed are respiratory issues, such as chronic pulmonary hypertension, bronchopulmonary dysplasia and susceptibility to viral infections, digestive issues, such as gastroesophageal reflux, oral aversion and malnutrition, and orthopaedic issues that include scoliosis (3) . The current management of these complications needs to start earlier than it does at the moment, ideally from the neonatal period, and patients with CDH require long-term follow-up and specialised Abbreviations CDH, Congenital diaphragmatic hernia; FETO, Foetal tracheal occlusion; O/E-LHR, Observed-to-expected lung area-to-head circumference ratio; PCO2, Partial pressure of carbon dioxide; PPHN, Persistent pulmonary hypertension of the newborn; SpO2, Arterial oxygen saturation.
Key notes
The French National Rare Disease Reference Center for congenital diaphragmatic hernia (CDH) was created in 2008, to implement a national protocol for foetuses and children with this serious condition. Neonatal mortality from CDH is 30-40% and half of those who live have high respiratory, nutritional and digestive morbidity. Organising health care and implementing a nationwide protocol were key factors for reducing mortality and morbidity from CDH in France. multidisciplinary care, due to the intricacy of these various complications.
In 2008, the Rare Disease Reference Center for congenital diaphragmatic hernia was created in France, and it is structured around the Lille Coordinating Center, the Bicetre-Paris Center, the Marseille Constituent Center and the 27 Competence Centers. The French Ministry of Health defined the conditions that were required to become reference and competence centres, such as expertise, recruitment and how patient care was organised. The CDH Rare Disease Reference Center has many purposes, including establishing healthcare procedures for foetuses and children with CDH, implementing standardised care across the France, developing clinical and research expertise and providing all patients with access to therapeutic and technological innovations. Three panels of experts, obstetricians, paediatricians and paediatric surgeons, have been set up to draft proposals for standardised and evidence-based prenatal, neonatal and surgical care. The groups were driven by the leaders of each of the Rare Disease Reference Centers. The first draft was reviewed by all the specialists involved in the Reference Centers, and any areas of disagreement were then discussed during four national meetings to reach a consensus. These national meetings involved experts from different disciplines-obstetricians, paediatricians, paediatric surgeons and geneticists-representatives of patient support groups and healthcare providers and psychologists, and specialists in human and social sciences. The document was then reviewed and approved by the National Health Agency, the Haute Autorit e de Sant e, and is currently available on the website of the French National Authority for Health. The reference centre coordinates a national database that collects prenatal and neonatal information from children, as well as long-term outcomes. It organises research and links with European and international networks and is a member of the European Reference Network for rare gastrointestinal diseases.
The national protocol for the care and treatment for children with CDH is based on three key principles: (i) improved knowledge of pathophysiology; (ii) continuous management from the foetal period to adulthood, including medical and surgical treatments and psychosocial support and (iii) optimisation of the medical and surgical management of the perinatal period, in particular the prenatal prevention and treatment of pulmonary arterial hypertension.
Most of the French Rare Disease Reference Centre for CDH guidelines are based on the EURO Consortium guidelines (4) .
Nevertheless, a number of differences exist between the two sets of guidelines.
First, the National Rare Diseases Plan for CDH management organises care based on a network of rare diseases centres.
Second, antenatal management is strictly protocolised in order to assess associated malformations and prognostic factors, and the patients are then signposted to a centre according to the expertise they need for optimal management.
Third, standardised intensive care is applied within the national network, and regular surveys are carried out to ensure that the national protocol is effectively implemented.
Fourth, with regard to intensive care management, the national guidelines aim to limit invasive procedures, for example no systematic intraradial catheters, and promote supportive care by the parents and healthcare providers, in order to reduce the need for sedative drugs. Surgery is performed early after birth, usually within the first 48 hours. Extubation is performed early after surgery, even in cases with pulmonary hypertension, as that is not considered a contraindication for surgery. Special care is taken to provide optimal parenteral nutrition and early enteral feeding. Pulmonary hypertension is not considered to require routine pulmonary vasodilator. Careful echocardiographic examination is performed to assess for postcapillary pulmonary hypertension for which pulmonary vasodilator is not required. Fluid resuscitation is not considered as a first-line treatment for hypotension, and only symptomatic hypotension is treated according to the main mechanism of the hypotension, namely vasoplegic, hypovolemic, cardiogenic or obstructive. Fifth, follow-up is organised according the individual needs of the patients. A network of specialists, including pneumo-paediatricians, nutritionists, speech-therapists, psychologists, neuro-paediatricians and coordinating physicians, is identified in each centre (Table 1) .
Finally, a national database records prospectively individual antenatal, postnatal data and follow-up data.
PHYSIOPATHOLOGY OF NEONATAL RESPIRATORY FAILURE
Congenital diaphragmatic hernia is associated with abnormal pulmonary development. The number of bronchial divisions is reduced, which explains the decrease in the number of bronchioles. As vascular development progresses with alveolar development, fewer pulmonary arterial branches are observed in CDH. Multiple functional abnormalities of pulmonary vessel reactivity have been reported. Pulmonary response to vasodilator stimuli is reduced. These structural vascular abnormalities, namely restrictive vascular bed and vascular wall remodelling, and these functional abnormalities cause a failure in the cardiorespiratory transition at birth. This foetal-to-neonatal maladaptation results in PPHN. This is associated with:
A right-to-left shunt through the ductus arteriosus and the foramen ovale, responsible for hypoxaemia; A reduction in the pulmonary venous return, resulting in a decrease in the filling pressures of the left ventricle and in the aortic flow; Right-sided heart failure, especially if the ductus arteriosus is closed. The right-sided heart failure alters the diastolic filling of the left ventricle, an additional factor for systemic low blood flow (5) (Fig. 1 ).
Furthermore, prenatal echocardiographic studies have shown a decreased left ventricular/right ventricular ratio and decreased left ventricular mass (6) . This lack of development of the left-sided heart was reproduced in an experimental study of foetal lamb with CDH. This feature should be distinguished from hypoplastic left-sided heart syndrome, with atresia of both the mitral and aortic valves. Underdevelopment of the left side of the heart is caused by reduced pulmonary venous return as a result of the decreasing pulmonary blood flow required for normal ventricular growth.
PRENATAL MANAGEMENT IN FRANCE Prognostic evaluation
As pulmonary hypoplasia and pulmonary arterial hypertension are the two main determinants of neonatal mortality and morbidity, the aim of prognostic evaluation is to predict their severity. Moreover, foetal surgery requires an accurate evaluation of the prognosis, a it must be reserved for the most severe cases. Prenatal assessment is important because it allows us to inform parents better, compare results from the different centres, select foetuses that can benefit from intrauterine surgery, prepare parents for the fact that the child may die during the neonatal period or allow them to choose a medical termination of pregnancy and reassure parents and not to agree to their Figure 1 Pulmonary circulation in persistent pulmonary hypertension. In congenital diaphragmatic hernia (CDH) infants, pulmonary vascular resistances (PVR) are elevated, leading to a decrease in pulmonary blood flow that, in turn, reduces the left ventricle preload. In that condition, the systemic blood flow is supported, at least in part, by the right ventricle outflow through the ductus arteriosus, reducing postductal SpO2. Oxygen supply is usually adequate as long as the ductus arteriosus is widely patent. Both aortic and pulmonary artery pressures are closely related when the ductus arteriosus is patent (low ductal resistance). This electrical representation further highlights that a patent ductus arteriosus and normal right ventricle function are required for sustaining systemic blood flow and oxygen supply.
request for a termination when the prognostic factors are good.
In practice, two procedures are systematically performed in France: the observed-to-expected lung area-to-head circumference ratio (O/E-LHR) and magnetic resonance imaging measurement of total foetal lung volume. O/E-LHR assesses contralateral pulmonary volume and therefore pulmonary hypoplasia. The sensitivity of this test in predicting survival is only 46% for a false-positive rate of 10%, regardless of the position of the liver (7). Prenatal magnetic resonance imaging of the O/E-FLV remains the gold standard (8) . Both lungs, including the ipsilateral lung, can be measured, whereas this is rarely possible on ultrasound.
In addition to the LHR and total foetal lung volume measurements, liver position plays a role in the prognostic evaluation. Liver position evaluation was initially qualitative, with only information on the abdominal or intrathoracic position of the liver. Magnetic resonance imaging has resulted in a more precise volumetric estimate of the portion of the ascending liver and improved prediction of survival. The evaluation of the liver position has been simplified by stomach position grading on the image sections used for LHR measurement. The closer the stomach is to the atrioventricular heart valves, the more the liver is ascended (9) .
In 2015, we published results based on a study of the national French database, which showed that an early gestational age at the time of the child's CDH diagnosis was associated with a high mortality rate (10) .
With the exception of karyotypes, no routine-advanced genetic analysis, such as exome or whole gene sequencing, is performed when there is an antenatal diagnosis of CDH.
The fetoscopic tracheal occlusion technique (FETO)
Lung liquid, produced by the respiratory epithelium, plays a crucial role in lung development. Lung liquid retention in the future air spaces is required to expand the lung and to promote its growth and maturation. Trachea ligation in foetal sheep has been shown to have a beneficial effect on pulmonary growth, vascularisation and the development of the gas exchange surface (11) . It has also been shown that the lung's response to tracheal ligation is dependent on the duration and timing of the occlusion. The optimum period for optimal growth and maturation of the lungs is between 28 and 34 weeks of gestation. Endotracheal balloon removal before birth releases fluid accumulated in alveoli and promotes surfactant secretion by pneumocytes II. That is why, as far as possible, the endotracheal balloon removal must be performed before delivery.
In 2001, Deprest and Nicolaides performed the first tracheal occlusion in the human foetus using an endoscopic technique to place a reversible balloon beneath the vocal cords (12) and they reported their first large series in 2009 (13) . They treated 175 foetuses with left-sided CDH, 34 foetuses with right-sided CDH and one with bilateral CDH. The median gestational age at the procedure was 27 weeks. Half of the patients experienced premature rupture of the membranes 3-83 days after surgery. The endotracheal balloon was removed, either by endoscopy or ultrasound-guided puncture during the prenatal period or by ultrasound-guided puncture or bronchoscopy-guided ablation immediately after birth. Delivery occurred at a median gestational age of 35 weeks, and 50% of the children were alive at hospital discharge. One randomised study of severe CDH cases showed an increase in survival for foetuses who received FETO, but the survival rate in the control group, who did not receive FETO, was very low (14) .
Preterm delivery before balloon removal is a possible complication of this technique. There are five possibilities for endotracheal balloon removal:
Intrauterine fetoscopic removal, which can be performed even after rupture of membranes, but not once labour has started; Postnatal removal, with the neonatologist or the ear, nose and throat specialist introducing the fetoscope under visual control and puncture of the balloon with a specially designed needle; Removal by the ear, nose and throat specialist with a 2.5 mm STORZ bronchoscope with an operator channel and crocodile clip; Intrauterine ultrasound-guided puncture of the balloon, but this technique is not always technically feasible and sometimes requires a transpulmonary approach to avoid injury of the neck blood vessels; Postnatal ultrasound-guided puncture of the balloon, but this is usually placed behind the sternum making this procedure hazardous.
Tracheal lesions were described early in the use of the technique, when endotracheal balloons were placed at an early gestational age. Indeed, we have observed tracheal lesions in children who underwent FETO (15), with segmental tracheomegaly and tracheal collapse at the end of the expiratory phase followed by progressive distension of the trachea at the inspiratory phase. Long-term studies are needed, but as FETO is no longer performed before 28 weeks of gestation, the rate of tracheal complications is low.
Two international trials that the Paris-Clamart Reference Center is participating in are currently in progress. 
DELIVERY ROOM AND INTENSIVE CARE MANAGEMENT
It is now well established that a standardised management protocol improves the prognosis of newborn infants with CDH (16) . Therefore, each centre is advised to draw up a specific care protocol, according to local conditions and based on the national programme for CDH management) The physician in charge of the centre is responsible for training the healthcare providers, coordinating the management and regularly evaluating the implementation of the protocol.
In addition, a clinical study of 2203 children with CDH suggests that mortality is lower in centres that manage more than six patients per year (17) . Prenatal transfer to a level three centre with a paediatric surgery department is required in cases of prenatal diagnosis (18) .
Guidelines for postnatal care have been proposed by the CDH EURO Consortium (4), based on data from the literature and expert advice from European centres specialising in the management of patients with CDH.
The objectives of medical management are threefold: to ensure tissue oxygenation and decarboxylation while minimising lung baro-volotrauma, to ensure adequate circulatory function by limiting the consequences of pulmonary hypertension and to prevent respiratory and digestive morbidity.
Delivery room management
The first successive procedures to be performed at birth are as follows:
-Provide intubation and ventilation with oxygen, despite the fact that the benefit of oxygen compared to air has not been demonstrated in infants with CDH; -Avoid mask ventilation to prevent gastric and intestinal distention, which may worsen pulmonary compression. The tube needs to be connected to a ventilator set at a maximum positive pressure level of between 18 and 24 cm of water, an end-of-expiration pressure from two to five cm water and a ventilatory rate of 40-60 cycles per minute (19) ; -Insert a gastric tube to decompress the stomach, although there is no evidence to validate this guideline; -Monitor vital parameters: heart rate, preductal and postductal arterial oxygen saturation (SpO 2 ), transcutaneous partial pressure of carbon dioxide, blood pressure and tidal volume; -Provide analgesia via a peripheral vein. There is no benefit in administering paralytic drugs in the delivery room (20) ; -Note that apart from premature birth, surfactant systematic administration is not recommended. Pulmonary content of dipalmitoyl phosphatidyl choline and surfactant protein expression is normal in a human foetus with CDH (21) . Intratracheal instillation of surfactant is associated with excess mortality and bronchopulmonary dysplasia (22) .
Neonatal intensive care
Mechanical ventilation is rapidly adapted to maintain a preductal SpO 2 value of 80-95% and a partial pressure of carbon dioxide (PaCO 2 ) value of 50-70 mmHg. Most CDH infants have persistent pulmonary hypertension with rightto-left shunt through the ductus arteriosus. Postductal SpO 2 is therefore usually lower than preductal SpO 2 . Normalisation of postductal SpO 2 necessitates reduced right-to-left shunt through the ductus arteriosus, thus reducing the level of pulmonary hypertension. To achieve this, hyperventilation was proposed, in order to obtain respiratory alkalosis, until studies demonstrated that hyperventilation was associated with baro-volotrauma lesions, such as pneumothorax and bronchopulmonary dysplasia (19) .
Data from physiology as well as clinical studies suggest that normalising postductal SpO 2 and PaCO 2 are not a vital necessity in CDH infants. Indeed, the preductal and postductal SpO2 gradient indicates that part of the blood flow from the pulmonary artery has been added to the flow of the descending aorta. Oxygen delivery is the product of arterial oxygen content by blood flow. Therefore, even if the oxygen arterial content decreases, the oxygen supply may be adequate as long as cardiac function is not impaired and the ductus arteriosus remains open (Fig. 1) . In addition, authors have reported a reduction in mortality and respiratory morbidity with a gentle ventilatory strategy, such as permissive hypercapnia, inspiratory pressure of less than 25 cm water and preductal SpO2 of more than 85% (23) . Highfrequency oscillation ventilation is considered as a means of preventing baro-volotrauma and is indicated in situations where there is persistent hypercapnia (PaCO2 > 60 mmHg) and, or, hypoxaemia (preductal SpO2 < 85%). A randomised study compared high-frequency oscillation ventilation and conventional ventilation in CDH infants. It found that although the primary outcome measure was similar in both groups, namely death and bronchopulmonary dysplasia, conventional ventilation was associated with a shorter duration of mechanical ventilation and less frequent use of inhaled nitric oxide, sildenafil and extracorporeal membrane oxygenation (24) . Therefore, conventional mechanical ventilation is recommended as a first-line ventilation mode. The ventilatory parameters should be reduced as soon as possible and adjusted to maintain preductal SpO2 from 80 to 95% and PaCO2 from 50 to 70 mmHg. To minimise barotrauma, the inspiratory pressure should not exceed 24cmH2O. If a pressure greater than 28 cmH2O is required to maintain target values of preductal SpO2 and PaCO2, high-frequency oscillation ventilation or extracorporeal membrane oxygenation should be considered.
Persistent pulmonary hypertension of the newborn is responsible for hypoxaemia secondary to a right-to-left shunt through the ductus arteriosus and the foramen ovale. The impact of this hypoxaemia on tissue oxygenation is likely to be modest as long as the SpO2 of the preductal area (cerebral oxygenation) is greater than 80% and as long as adequate cardiac function is maintained and the haemoglobin concentration is normal. Thus, hypoxaemia during foetal life or during cyanogenic congenital heart disease is not associated with tissue hypoxia provided that there is normal cardiac function.
However, PPHN is frequently associated with impaired cardiac function affecting both the left and right side of the heart. Right-sided heart failure occurs when the ductus arteriosus becomes restrictive, which increases the right ventricle afterload.
Right-sided heart failure alters left ventricular diastolic filling, which is an additional factor in decreased left ventricular flow. Low aortic flow decreases the delivery of oxygen to the tissues, which involves an increase in tissue oxygen extraction to maintain oxygen consumption and induces a drop in venous partial pressure of oxygen. Pulmonary vascular tone is dependent on the oxygen environment of the arteriolar vessels. The decline in PvO2 is therefore a worsening factor of PPHN. In total, the circulatory consequences of PPHN on mortality are probably more important than the consequences of PPHN on PaO2. In other words, rather than striving to normalise postductal SpO2, the main goal is to optimise circulatory function in CDH infants. Therefore, it is essential to evaluate and treat effectively the haemodynamic consequences of PPHN.
The usual clinical expression of PPHN is unstable refractory hypoxaemia with a preductal and postductal SpO2 gradient. The circulatory consequence of PPHN is an obstructive shock and the clinical and biological features of this are nonspecific: grey skin colour, tachycardia, a capillary refill time of more than three-seconds, oliguria, hypotension and lactic acidosis. Echocardiography highlights signs of pulmonary hypertension, such as a bidirectional shunt or right-left shunt by the ductus arteriosus, flattening of the interventricular septum or even inversion of the septal curvature and high-velocity tricuspid regurgitation. The velocity of blood flow through the ductus arteriosus is a reliable estimate of the pulmonary arterial pressure.
These signs of pulmonary hypertension may be associated with signs of right heart failure, in terms of a dilated right ventricle and contractile dysfunction, and left heart failure.
The left ventricle appears compressed by the right ventricle, and the mean velocities of the blood flow in the isthmicaorta are decreased or even retrograded (5) . Left-sided heart failure is related to decreased pulmonary venous return and to right heart failure, which limits left ventricle diastolic filling. This occurs when pulmonary arterial pressures are suprasystemic (25) . In this case, transmural pressures of the right ventricle are higher than coronary pressure, resulting in right ventricle ischaemia. Pulmonary arterial pressure may be suprasystemic when the ductus arteriosus is restrictive. In this case, the velocities of the left-to-right shunt in the ductus arteriosus are elevated. As long as the ductus arteriosus is largely patent, as it is during intrauterine life, pulmonary artery and aortic pressures are equal. Therefore, prostaglandin E1 infusion helps to reduce right-sided heart failure and thus improve left ventricle diastolic dysfunction by reducing pulmonary artery pressure to the systemic level, improving perfusion of the descending aorta through the pulmonary artery (26) .
Many environmental factors may worsen PPHN. Stress and pain increase pulmonary vascular resistance by activating alpha one adrenergic receptors (27, 28) . Stress factors, such as noise, tactile stimulation, tracheal suctioning and heel pricks, must only be carried out when it is strictly necessary. Analgesia must be adjusted according to the assessment of a pain and, or, discomfort score. The French national guidelines recommend that clinicians do not use routine muscle relaxation as well as sedation. Benzodiazepine may decrease systemic vascular resistance and systemic pressure that in turn may decrease pulmonary artery pressure when the ductus arteriosus is open. Pulmonary blood flow depends, at least partly, on pulmonary artery pressure. Benzodiazepine may, therefore, decrease the pulmonary blood flow. Lung overdistension is another factor of reduced pulmonary blood flow. It can occur when the mean ventilatory pressure is high. This is an additional argument for not recommending hyperventilation methods.
In cases of hypovolaemia, fluid resuscitation with saline is recommended. Adrenal insufficiency is common in this context, and hydrocortisone can be used in cases of systemic hypotension (29) . In cases of shock, vasoactive and inotropic treatment should be initiated. Norepinephrine has been shown to be effective during obstructive shock (5, (30) (31) (32) .
Inhaled nitric oxide is currently recommended for newborn infants with PPHN. Improved PaO2 has been reported in children with CDH. However, there is currently no evidence that inhaled nitric oxide improves outcomes in CDH infants. Early use of inhaled nitric oxide does not change mortality in children with CDH. Greater use of extracorporeal membrane oxygenation has been observed in CDH infants treated with inhaled nitric oxide (33) . Thus, there is little evidence to recommend first-line nitric oxide inhalation in CDH. Its use should be limited to severe PPHN after optimising alveolar ventilation and correcting haemodynamic disorders. On the other hand, studies have shown the benefit of inhaled nitric oxide in CDH cases that have the added complication of chronic pulmonary hypertension (34) .
If the response to inhaled nitric oxide is insufficient, intravenous or subcutaneous prostacyclin or oral sildenafil may be used (35, 36) . Data on the recommend use of intravenous sildenafil or milrinone are lacking. A European randomised trial is currently in progress to compare inhaled nitric oxide and intravenous sildenafil.
Extracorporeal membrane oxygenation is a technique that aimed to ensure adequate oxygenation and decarboxylation and to limit lung baro-volotrauma and it is indicated in cases of refractory hypoxaemia and obstructive shock, despite optimal medical management. The usual criteria for using extracorporeal membrane oxygenation for infants with CDH are preductal SpO2 pf less than 80% and a peak inspiratory pressure of more than 28 cmH2O, and circulatory failure. The survival of infants with severe forms of CDH after extracorporeal membrane oxygenation is about 50% (3).
Specificities of perioperative and postoperative management
The timing for surgical diaphragm closure is still controversial. Two randomised studies compared early surgery before 24 hours to delayed surgery after 48 hours and found that mortality was similar in both groups. Nevertheless, a trend towards prolonged duration of mechanical ventilation and hospital stays have been observed in cases of delayed surgery (37, 38) . The general medical management procedures described above are the same in postoperative management. Nevertheless, one should pay particular attention to limit the risk of barotrauma and aggravation of pulmonary hypertension during and after the surgical procedure. The surgical procedure should ideally be performed in the neonatal intensive care unit so that the child is not moved when they are in an unstable condition. Continuous monitoring of preductal and postductal SpO2 and transcutaneous PaCO2 is required to optimise mechanical ventilation during and after surgery. The benefits of using, or not using, postoperative pleural drains have not been demonstrated. Optimal analgesia based on the use of a validated newborn pain scale is necessary to prevent pulmonary hypertension (27, 28) .
PREVENTING RESPIRATORY AND DIGESTIVE MORBIDITY
Half of the children with CDH have high levels of morbidity, and the main sequelae are respiratory, digestive and nutritional. It should be stressed that the current management of these complications starts too late and should start from the neonatal period.
Nutritional disorders occur in about half of the children with CHD (3), and the origin of these nutritional disorders is multifactorial, including gastroesophageal reflux, oral aversion, late oral intake, dys-stimulation of the buccal region by multiple oral and pharyngeal suction. Gastrooesophageal reflux should, therefore, be prevented by postural treatment and drug therapy. Gastric suction must be limited to the preoperative and immediate postoperative period. Special care should be taken not to stimulate the nausea reflex during nasopharyngeal suction procedures. Oral feeding is proposed at an early stage after surgery. Surgery is performed as soon as the respiratory and haemodynamic stabilisation is obtained, usually before 48 hours, to prevent unnecessary delays in oral feeding. Oral stimulation should start early according to a validated protocol and the period of enteral tube feeding should be limited.
Breastfeeding is recommended and to ensure this is possible breast milk expression should be encouraged before eight hours after delivery and then six-eight times a day. Breastfeeding is best, but a cup or straw can be used if this is not possible. If a baby bottle is used, a short physiological nipple is preferable. In addition to preventing viral infections and allergic risks, breastfeeding is an effective way of limiting cows' milk protein allergy, which is more common in children who have undergone abdominal surgery (39).
As stated above, nearly half of the surviving CDH children have sequelae and they require specialist, multidisciplinary care and follow-up, including pneumo-paediatricians, gastropaediatricians, nutritionists, paediatric surgeons, psychologists and neonatologists. Follow-up must be organised before hospital discharge at a multidisciplinary meeting, due to the intricacy of the various complications involved. The provision of the psychosocial support that the families of CDH children need, including quality of life, early rehabilitation, and preventing nutritional disorders and managing chronic disorders, is currently insufficient in France. It must begin from the antenatal period and be continued until adolescence. Consistent information and support should be ensured to avoid breaks during the transition from foetal life to the neonatal period and then to childhood due to the number of specialists involved.
CONCLUSION
The aim of implementing a nationwide protocol for managing infants with CDH is to reduce neonatal mortality, which may be improved by the standardisation and organisation of the health care. We also need to recognise that severe morbidity may be responsible for late mortality and that in many cases, this is not assessed well (3). Thus, measures to prevent morbidity should be implemented from birth, as a key factor in the prognosis of CDH.
Prospective follow-up is also a prerequisite for better understanding the evolutionary profile of this disease and has been implemented to evaluate strategies for prenatal and postnatal care, prevent complications and morbidity related to CDH and to inform parents in the prenatal and postnatal periods of their child's future.
At the time of writing this review, 1016 CDH infants, about 130 per year, were included in the national database. Foetal loss due to termination of the pregnancy and foetal death was recorded in 12% of the prenatal diagnoses. In 60% of terminations, the foetus had been diagnosed with chromosomic or genetic diseases. Congenital diaphragmatic hernia was diagnosed postnatally in 22, and 30% of the infants died before they could be discharged home. The outcome at one year of age in the national cohort has been explored and will be published (40) .
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